Xiamen Amoytop Biotech Co Ltd Free Cash Flow Generation Index

Latest as of September 2023: 0.87x

Xiamen Amoytop Biotech Co Ltd free cash flow generation index. Xiamen Amoytop Biotech Co Ltd (688278) has a Free Cash Flow Generation Index of 0.87x as of September 2023. Free cash flow of CN¥289.29 Million represents 1% of operating cash flow (CN¥332.29 Million).

FCF Generation Index

0.87x
Free Cash Flow / Operating CF

Free Cash Flow

CN¥289.29 Million
CNY

Operating Cash Flow

CN¥332.29 Million
CNY

Capital Expenditures

CN¥43.00 Million
CNY

Free Cash Flow Generation Index of Xiamen Amoytop Biotech Co Ltd (2016–2024)

Free cash flow generation index of Xiamen Amoytop Biotech Co Ltd from 2016 to 2024. Historical FCF Generation Index trend for Xiamen Amoytop Biotech Co Ltd across 8 annual periods. See 688278 free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.

Xiamen Amoytop Biotech Co Ltd Free Cash Flow Generation Index by Year (2016–2024)

Xiamen Amoytop Biotech Co Ltd free cash flow generation index by year from 2016 to 2024. Year-by-year Free Cash Flow Generation Index for Xiamen Amoytop Biotech Co Ltd. For the full cash flow conversion analysis, see Xiamen Amoytop Biotech Co Ltd cash flow conversion.

Year FCG Index Free Cash Flow (CNY) Operating CF Capital Expenditures YoY Change
2024 0.42x CN¥179.28 Million CN¥430.63 Million CN¥251.35 Million ▼ -22.4%
2023 0.54x CN¥274.86 Million CN¥512.10 Million CN¥244.48 Million ▲ +35.4%
2022 0.40x CN¥143.99 Million CN¥363.16 Million CN¥219.17 Million ▲ +112.3%
2021 0.19x CN¥43.85 Million CN¥234.78 Million CN¥190.93 Million ▲ +166.0%
2020 -0.28x CN¥-26.20 Million CN¥92.61 Million CN¥118.81 Million ▼ -144.5%
2019 0.64x CN¥78.48 Million CN¥123.30 Million CN¥44.83 Million ▼ -23.9%
2018 0.84x CN¥74.55 Million CN¥89.15 Million CN¥14.60 Million ▼ -72.6%
2016 3.05x CN¥129.46 Million CN¥42.43 Million CN¥87.03 Million —
FCG Index = Free Cash Flow / Operating Cash Flow. FCF = Operating CF + Capital Expenditures (capex stored negative).